Propagermanium, a CCL2 inhibitor, has shown promising results, downregulating serum IL‐6 levels in a phase I clinical trial, as well as demonstrating clinical safety and holding potential as an antimetastatic agent in breast cancer treatment [43]. This evidence concerns the gene IL6 and breast carcinoma.